Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 6/20 | 0.56 |
| ▸ | DAGLA | Q9Y4D2 | 3/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA4 | P22748 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16858484 | 0.87 | TAS2R14 (0.64) | TAS2R14DAGLAKEAP1NFE2L2 | |
| SCHEMBL21315101 | 0.84 | NR1D1 (0.56) | TAS2R14MMP1MMP2MMP9MMP8 | |
| SCHEMBL5191217 | 0.81 | TAS2R14 (0.71) | TAS2R14DAGLAPOLB | |
| SCHEMBL25225813 | 0.81 | TAS2R14 (0.59) | TAS2R14DAGLAMMP1MMP2MMP9 | |
| SCHEMBL4656751 | 0.81 | ALDH1A1 (0.66) | TAS2R14KEAP1 | |
| SCHEMBL7961836 | 0.79 | KEAP1 (0.68) | TAS2R14MMP1MMP2MMP9MMP8 | |
| SCHEMBL13171920 | 0.79 | KMT2A (0.64) | TAS2R14DAGLACA12CA1CA2 | |
| SCHEMBL27192066 | 0.78 | CNR2 (0.46) | TAS2R14 | |
| SCHEMBL30701971 | 0.78 | CNR2 (0.46) | TAS2R14 | |
| SCHEMBL17137126 | 0.78 | ALDH1A1 (0.54) | TAS2R14KEAP1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4501932-A2 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| EP-3880208-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-11-20 | — | — | EP | disclosed |
| EP-3880208-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-09-22 | — | — | EP | disclosed |
| US-20200308170-A1 | KRAS G12C INHIBITORS | ARRAY BIOPHARMA INC. | 2020-10-01 | — | — | US | disclosed |
| WO-2020101736-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-10647715-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190270743-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647715-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | TAS2R14 4382/4885DAGLA 1662/4885MMP1 3508/4885 |
| US-20200308170-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | TAS2R14 4382/4885DAGLA 1662/4885MMP1 3508/4885 |
| US-20190270743-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | TAS2R14 4382/4885DAGLA 1662/4885MMP1 3508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.